Loading…
Loading…
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.
[url="]Amentum[/url] (NYSE: AMTM), a global leader in advanced engineering and technology solutions, has been awarded NASA's Consolidated Spaceflight Mission O
SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.
Shares of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are rallying sharply Thursday, hitting a fresh 52-week high of $11.06, up over 16% in midday trading. The clinical-stage biopharmaceutical company is experiencing a massive surge in volume following a regulatory filing.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for SLS and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.